EpiPen patent revoked in Europe
Amy Kerkemeyer / Shutterstock.com
EpiPen buyers have secured final approval of a $345 million settlement with Pfizer in a consumer antitrust suit.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Antitrust, Pfizer, US District Court for the District of Kansas, Daniel Crabtree, EpiPen, Class-action, big pharma